Therapy with Skyrizi is 600mg given by infusion at weeks zero, four and eight, followed by a 360mg subcutaneous shot given at week 12 and every eight weeks thereafter. The FDA is also reviewing a ...

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster. Skyrizi is important for AbbVie as sales of its ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...